How Long Does Ashwagandha Take to Work for Anxiety?

This guide walks through the timeline from the published trials, separates stress from anxiety (the research treats them differently), and covers the dose, extract type, and safety checks that make the difference between "nothing happened" and "this actually helped."

Stress vs Anxiety: The Trials Measure Different Things

The best-known ashwagandha stress trials — Chandrasekhar et al. (2012, 60 days) and Salve et al. (2019, 8 weeks) — enrolled stressed-but-otherwise-healthy adults and measured perceived stress (PSS), not diagnosed anxiety disorders. Pratte et al.'s 2014 systematic review (5 RCTs) is the closest thing to an anxiety-specific evidence base — and it concluded the data were promising but that more rigorous trials were needed.

Translation: ashwagandha has decent evidence for stress reduction and modest, preliminary evidence for anxiety reduction. Most of what follows is stress-trial timing, which is the stronger foundation. For diagnosed anxiety disorders, no trial supports replacing professional treatment.

The Timeline: What to Expect and When

Week by Week, From the Trials

Week 1: baseline, plus adjustment effects. There's no trial basis for same-week anxiolysis; anyone claiming overnight results is extrapolating from nothing. No trial reported a sedation signal (Chandrasekhar's adverse events were mild and comparable between groups; Salve reported zero); NCCIH does note that in some individuals ashwagandha may cause drowsiness, stomach upset, diarrhea, and vomiting.

Weeks 2–4: no separation yet. In Chandrasekhar et al. (2012) — 64 stressed adults enrolled (61 completed Day 60), 300 mg KSM-66 twice daily — perceived-stress scores fell 44.0% vs 5.5% placebo (p<0.0001) and serum cortisol fell 27.9% (p=0.0006), measured at endpoint only. Salve et al. (2019) — 60 stressed adults (PSS ≥20, no psychiatric illness), 125 mg or 300 mg capsules twice daily (= 250/600 mg/day) for 8 weeks — found dose-dependent stress reduction (PSS p<0.05 at 250 mg, p<0.001 at 600 mg; cortisol p<0.05 / p<0.0001). But Salve's week-4 scores had not separated from placebo; significance was reported at 8 weeks.

Weeks 6–8: the main effect window. This is where the 8-week trials show their results — anxiety and stress scores significantly below placebo at endpoint (Pratte's 2014 systematic review found all five RCTs favored ashwagandha, with two of three HAM-A trials significant). Sleep improvements follow a similar arc: Langade et al. (2019) — 60 insomnia patients, 2:1 randomization, 300 mg root extract twice daily, 10 weeks — found sleep-onset latency significantly shorter at 10 weeks (29.00 vs 33.94 min, p=0.019) and sleep efficiency improved (83.48 vs 79.68), with between-group separation significant only at 10 weeks, not at 5. Sleep and anxiety interact, so better sleep may be part of what users "feel" first.

Weeks 8–10: fullest effects. Langade 2019 (10 weeks) is the longest published anxiety/stress trial; no 12-week trial with anxiety or stress outcomes in a general population has been published (a 12-week KSM-66 RCT is registered but unpublished). The effect appears to build rather than plateau early.

Beyond 10 weeks: unknown territory for trials. Traditional use is long-term and ongoing, but no published trial data past 10 weeks exists for stress/anxiety outcomes. NCCIH states: "There is not enough information to allow conclusions about long-term safety to be reached." Case reports of ashwagandha-associated liver injury exist — including a five-case series (Björnsson et al., Liver Int. 2020; PMID 31991029): cholestatic or mixed injury after 2–12 weeks, self-limited, no hepatic failure — rare, but a reason not to use indefinitely without breaks and monitoring.

The Doses the Timeline Is Based On

The timeline above only applies at trial doses:

A 300 mg once-daily capsule of unknown extract strength is not the studied regimen. And "300 mg of root powder" (crude) is not the same as 300 mg of a standardized extract — KSM-66 is standardized to ≥5% withanolides (HPLC, per the Chandrasekhar paper and Ixoreal specs).

KSM-66 vs Sensoril: Does Extract Type Change the Timeline?

The two major studied extracts differ:

• KSM-66 — root-only extract, "full spectrum" (standardized to ≥5% withanolides by HPLC), the extract in Chandrasekhar, Choudhary, and Salve
• Sensoril — root-plus-leaf extract, standardized to ≥10% withanolide glycosides and ≥32% oligosaccharides (withaferin A <0.5%)

Sensoril has its own trial base at lower mg doses — e.g., Auddy et al. 2008 (125 mg once or twice daily, or 250 mg twice daily, 60 days) and Pingali et al. 2014 (250 mg twice daily, 60 days). No published head-to-head trial comparing the two for anxiety has been located, so any "faster/better" claim for one over the other is marketing, not evidence. Both have 6–8+ week timelines in their own trials.

When It's Fair to Say It Isn't Working

Give it 8 weeks at a trial-equivalent dose (e.g., 300 mg of a studied standardized extract twice daily). If perceived stress and anxiety are unchanged at that point, the trial evidence doesn't suggest more time will help — these trials showed separation from placebo by week 8, not week 16. Common reasons for "failure" that are really dosing problems:

1. Dose too low — one 300 mg capsule daily is half the studied stress dose
2. Wrong extract — crude powder or unstandardized blends aren't the trial material
3. Expectation mismatch — it's a gradual modulator, not an anxiolytic drug; people expecting Xanax-like speed will always be disappointed
4. Underlying condition — clinical anxiety disorders need professional treatment; no supplement trial supports self-treatment of diagnosed disorders

Safety: Who Should Skip or Check First

The trial record is reasonably reassuring short-term, but real cautions exist:

• Pregnancy: avoid. NCCIH's exact wording: "Ashwagandha should be avoided during pregnancy and should not be used while breastfeeding."
• Thyroid: Sharma et al. (2018) — 50 adults with subclinical hypothyroidism, 300 mg aqueous root extract (5% withanolides) twice daily, 8 weeks — found TSH −17.4%, T4 +19.6%, T3 +41.5% (all significant vs placebo) — relevant if you take thyroid medication
• Liver injury: rare case reports, including a five-case series (Björnsson et al., Liver Int. 2020; PMID 31991029); anyone with liver disease should discuss with their clinician
• Sedatives/surgery: additive drowsiness with sleep drugs or alcohol is plausible (no controlled interaction trials); stop 2 weeks before planned surgery (WebMD; NCCIH advises against use before surgery without specifying a window)
• Autoimmune conditions: MSKCC notes ashwagandha "may also trigger or exacerbate autoimmune diseases" — clinician guidance needed
• Nightshade allergy: ashwagandha (Withania somnifera) is in the nightshade (Solanaceae) family; the Chandrasekhar paper itself cautions that those allergic to Solanaceae herbs should not take it

📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.

Explore the Full Remedy Database

Browse 500+ organic alternatives for health, wellness, and natural living.